Objectives: Our previous study confirmed systemic lupus erythematosus (SLE) associated with polymorphisms of PHLDB1 and WDFY4 genes. In this study, we investigatedthe clinical relevance of PHLDB1 and WDFY4 in SLE pathogenesis and their potential as biomarkers.
Methods: A total of 634 SLE patients from Sichuan University West China Hospital and 400 age- and sex-matched healthy controls were included in this study. Serum PHLDB1 and WDFY4 of SLE patients and HCs were measured by ELISA, and the laboratory indicators were collected through the electronic medical record. LASSO, logistic regression, and random forest models for SLE diagnosis and LN prediction, including variables: age, sex, serum proteins (PHLDB1/WDFY4), genotypes, cytokines, and clinical markers.
Results: Results revealed elevated PHLDB1 in SLE patients compared to controls (1.61 vs. 1.48 ng/mL, P = 0.025), while paradoxically showing suppression in LN versus Non-LN patients (1.42 vs. 1.52 ng/mL, P = 0.031). WDFY4 specifically increased in LN (666.59 vs. 594.57 pg/mL, P < 0.001) without systemic SLE alterations. Machine learning models incorporating these biomarkers demonstrated diagnostic utility, with random forest achieving AUC 0.843 for SLE discrimination and AUC 0.990 for LN prediction. LN patients concurrently exhibited distinct immune dysregulation (reduced IL-6/IL-17 and elevated TNF-α/IL-18) and renal metabolic impairment. These findings position PHLDB1 as a systemic SLE biomarker and WDFY4 as a LN-specific blood indicator, showing promise for clinical subtyping applications. Further validation of these stratified biomarkers is warranted.
Conclusion: Our results confirm a correlation between the serum levels of PHLDB1 and the occurrence of SLE.
目的:我们之前的研究证实了系统性红斑狼疮(SLE)与PHLDB1和WDFY4基因多态性相关。在这项研究中,我们研究了PHLDB1和WDFY4在SLE发病机制中的临床相关性及其作为生物标志物的潜力。方法:选取四川大学华西医院SLE患者634例和年龄、性别匹配的健康对照400例。采用ELISA法检测SLE患者和hc患者血清PHLDB1和WDFY4,并通过电子病案收集实验室指标。LASSO、logistic回归和随机森林模型用于SLE诊断和LN预测,包括变量:年龄、性别、血清蛋白(PHLDB1/WDFY4)、基因型、细胞因子和临床标志物。结果:结果显示,与对照组相比,SLE患者的PHLDB1升高(1.61 vs 1.48 ng/mL, P = 0.025),而LN患者的PHLDB1却受到抑制(1.42 vs 1.52 ng/mL, P = 0.031)。WDFY4在LN中特异性升高(666.59 vs 594.57 pg/mL, P)。结论:我们的研究结果证实了PHLDB1的血清水平与SLE的发生之间存在相关性。
{"title":"PHLDB1 and WDFY4 as dual-state biomarkers in SLE pathogenesis and lupus nephritis prediction.","authors":"Jianzhao Zhai, Lei Zhang, Wei Jia, Yue Pan, Ping Zhang, Qingyu Zou, Yongkang Wu","doi":"10.1186/s12865-026-00804-0","DOIUrl":"10.1186/s12865-026-00804-0","url":null,"abstract":"<p><strong>Objectives: </strong>Our previous study confirmed systemic lupus erythematosus (SLE) associated with polymorphisms of PHLDB1 and WDFY4 genes. In this study, we investigatedthe clinical relevance of PHLDB1 and WDFY4 in SLE pathogenesis and their potential as biomarkers.</p><p><strong>Methods: </strong>A total of 634 SLE patients from Sichuan University West China Hospital and 400 age- and sex-matched healthy controls were included in this study. Serum PHLDB1 and WDFY4 of SLE patients and HCs were measured by ELISA, and the laboratory indicators were collected through the electronic medical record. LASSO, logistic regression, and random forest models for SLE diagnosis and LN prediction, including variables: age, sex, serum proteins (PHLDB1/WDFY4), genotypes, cytokines, and clinical markers.</p><p><strong>Results: </strong>Results revealed elevated PHLDB1 in SLE patients compared to controls (1.61 vs. 1.48 ng/mL, P = 0.025), while paradoxically showing suppression in LN versus Non-LN patients (1.42 vs. 1.52 ng/mL, P = 0.031). WDFY4 specifically increased in LN (666.59 vs. 594.57 pg/mL, P < 0.001) without systemic SLE alterations. Machine learning models incorporating these biomarkers demonstrated diagnostic utility, with random forest achieving AUC 0.843 for SLE discrimination and AUC 0.990 for LN prediction. LN patients concurrently exhibited distinct immune dysregulation (reduced IL-6/IL-17 and elevated TNF-α/IL-18) and renal metabolic impairment. These findings position PHLDB1 as a systemic SLE biomarker and WDFY4 as a LN-specific blood indicator, showing promise for clinical subtyping applications. Further validation of these stratified biomarkers is warranted.</p><p><strong>Conclusion: </strong>Our results confirm a correlation between the serum levels of PHLDB1 and the occurrence of SLE.</p>","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":" ","pages":"16"},"PeriodicalIF":2.7,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-22DOI: 10.1186/s12865-025-00788-3
Zhuoyue Li, Wenjuan Guo, Rong Wang, Kun Zhang
{"title":"Analysis of risk factors of coronary artery lesions in Kawasaki disease and study of IVIG treatment response.","authors":"Zhuoyue Li, Wenjuan Guo, Rong Wang, Kun Zhang","doi":"10.1186/s12865-025-00788-3","DOIUrl":"10.1186/s12865-025-00788-3","url":null,"abstract":"","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":" ","pages":"10"},"PeriodicalIF":2.7,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12874742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-22DOI: 10.1186/s12865-026-00801-3
Chenxi Cui, ShuMei Rao, Yingying Liu
{"title":"Diagnostic and prognostic value of deregulated miR-6822-3p in patients with severe pneumonia.","authors":"Chenxi Cui, ShuMei Rao, Yingying Liu","doi":"10.1186/s12865-026-00801-3","DOIUrl":"10.1186/s12865-026-00801-3","url":null,"abstract":"","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":" ","pages":"14"},"PeriodicalIF":2.7,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-20DOI: 10.1186/s12865-026-00803-1
Guanjiankao Huang, Xuemei Li
{"title":"The impact of yak versus cow milk on exercise-induced allergy and performance in sensitized mice.","authors":"Guanjiankao Huang, Xuemei Li","doi":"10.1186/s12865-026-00803-1","DOIUrl":"10.1186/s12865-026-00803-1","url":null,"abstract":"","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":" ","pages":"13"},"PeriodicalIF":2.7,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12903737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146008811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-19DOI: 10.1186/s12865-026-00802-2
Wenjie Wu, Ting Zhong, Xiaolong Zhou, Weiqiong Chen, Xing Zhang, Huiming Xu, Zian Tang, Wenkai He, Yijian Wang, Gongrang Chen, Yan Wang, Boyu Liu, Yingjie Liu, Yongping Han, Kaili Lu, Yaoheng Wang, Bing Zhang, Lingjun Xiao, Ziyun Du, Quan Liu, Juan Liang, Xiantao Li, Lianxi Song
Background: Brain metastasis (BM) remains a major therapeutic challenge in non-small cell lung cancer (NSCLC) without actionable driver mutations. Radiotherapy combined with immune checkpoint inhibitors (ICIs) may enhance intracranial control through synergistic immune activation. This study evaluated the efficacy of radiotherapy plus ICI and explored prognostic factors influencing outcomes in patients with NSCLC-BM.
Methods: We retrospectively analyzed 116 patients with measurable, driver-negative NSCLC-BM treated between June 2019 and December 2024. Patients were divided into two groups: Radiotherapy combined with ICI plus chemotherapy (RT + ICI, n = 56) and ICI plus chemotherapy (ICI, n = 60). Intracranial and systemic objective response rates (iORR, sORR) and progression-free survival (iPFS, sPFS) were analyzed. Prognostic factors, including the prognostic nutritional index (PNI), were assessed using Cox regression analyses.
Results: Compared with the ICI group, the RT + ICI group demonstrated a significantly higher iORR (78.6% vs 40.0%, P < 0.001) and significantly longer median iPFS (11.8 vs 7.9 months; hazard ratio [HR] = 0.48, 95% confidence intervals [CI] 0.30-0.77, P = 0.002), and sPFS (8.9 vs 5.9 months; HR = 0.58, 95% CI 0.38-0.89, P = 0.014). High PNI (≥ 42.15) was independently associated with prolonged iPFS (HR = 8.77, 95% CI 2.91-26.47, P < 0.001) and sPFS (HR = 8.46, 95% CI 3.39-21.10, P < 0.001).
Conclusion: Radiotherapy combined with immunochemotherapy was associated with improved intracranial and systemic outcomes compared to immunochemotherapy alone in patients with driver-negative NSCLC-BM. Additionally, PNI shows potential as a useful biomarker for predicting therapeutic outcomes.
背景:脑转移(BM)仍然是非小细胞肺癌(NSCLC)的主要治疗挑战,没有可操作的驱动突变。放疗联合免疫检查点抑制剂(ICIs)可通过协同免疫激活增强颅内控制。本研究评估了放疗加ICI的疗效,并探讨了影响NSCLC-BM患者预后的因素。方法:我们回顾性分析了2019年6月至2024年12月期间接受治疗的116例可测量的驱动阴性NSCLC-BM患者。患者分为放疗联合ICI +化疗组(RT + ICI, n = 56)和ICI +化疗组(ICI, n = 60)。分析颅内和全身客观缓解率(iORR, sORR)和无进展生存期(iPFS, sPFS)。使用Cox回归分析评估预后因素,包括预后营养指数(PNI)。结果:与ICI组相比,RT + ICI组的iORR显著高于ICI组(78.6% vs 40.0%), P结论:与单独免疫化疗相比,放疗联合免疫化疗可改善驱动阴性NSCLC-BM患者的颅内和全身预后。此外,PNI显示出作为预测治疗结果的有用生物标志物的潜力。
{"title":"Brain radiotherapy combined with immune checkpoint inhibitors and chemotherapy as first-line treatment for advanced non-small cell lung cancer with brain metastases: a retrospective study.","authors":"Wenjie Wu, Ting Zhong, Xiaolong Zhou, Weiqiong Chen, Xing Zhang, Huiming Xu, Zian Tang, Wenkai He, Yijian Wang, Gongrang Chen, Yan Wang, Boyu Liu, Yingjie Liu, Yongping Han, Kaili Lu, Yaoheng Wang, Bing Zhang, Lingjun Xiao, Ziyun Du, Quan Liu, Juan Liang, Xiantao Li, Lianxi Song","doi":"10.1186/s12865-026-00802-2","DOIUrl":"10.1186/s12865-026-00802-2","url":null,"abstract":"<p><strong>Background: </strong>Brain metastasis (BM) remains a major therapeutic challenge in non-small cell lung cancer (NSCLC) without actionable driver mutations. Radiotherapy combined with immune checkpoint inhibitors (ICIs) may enhance intracranial control through synergistic immune activation. This study evaluated the efficacy of radiotherapy plus ICI and explored prognostic factors influencing outcomes in patients with NSCLC-BM.</p><p><strong>Methods: </strong>We retrospectively analyzed 116 patients with measurable, driver-negative NSCLC-BM treated between June 2019 and December 2024. Patients were divided into two groups: Radiotherapy combined with ICI plus chemotherapy (RT + ICI, n = 56) and ICI plus chemotherapy (ICI, n = 60). Intracranial and systemic objective response rates (iORR, sORR) and progression-free survival (iPFS, sPFS) were analyzed. Prognostic factors, including the prognostic nutritional index (PNI), were assessed using Cox regression analyses.</p><p><strong>Results: </strong>Compared with the ICI group, the RT + ICI group demonstrated a significantly higher iORR (78.6% vs 40.0%, P < 0.001) and significantly longer median iPFS (11.8 vs 7.9 months; hazard ratio [HR] = 0.48, 95% confidence intervals [CI] 0.30-0.77, P = 0.002), and sPFS (8.9 vs 5.9 months; HR = 0.58, 95% CI 0.38-0.89, P = 0.014). High PNI (≥ 42.15) was independently associated with prolonged iPFS (HR = 8.77, 95% CI 2.91-26.47, P < 0.001) and sPFS (HR = 8.46, 95% CI 3.39-21.10, P < 0.001).</p><p><strong>Conclusion: </strong>Radiotherapy combined with immunochemotherapy was associated with improved intracranial and systemic outcomes compared to immunochemotherapy alone in patients with driver-negative NSCLC-BM. Additionally, PNI shows potential as a useful biomarker for predicting therapeutic outcomes.</p>","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":" ","pages":"12"},"PeriodicalIF":2.7,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12903702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic value of systemic immune-inflammation index to albumin ratio (SAR) for long-term all-cause mortality in sepsis survivors: evidence from a multicenter cohort with up to 6 years of follow-up.","authors":"Yanni Tan, Minghui Wu, Zhenwei Zhai, Quan Lu, Haolun Wang, Jingxia Sun, Qiu Wang, Junyu He, Jinming Yu, Jianhao Huang, Wenxin Chu, Wensheng Lu","doi":"10.1186/s12865-026-00799-8","DOIUrl":"10.1186/s12865-026-00799-8","url":null,"abstract":"","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":" ","pages":"8"},"PeriodicalIF":2.7,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12860170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145970570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-09DOI: 10.1186/s12865-025-00793-6
Anjian Yan, Chang Lu, Xuening Wang
Background: The diversity of clinical symptoms of neonatal sepsis leads to difficulties in diagnosis, and the treatment is limited. This study aims to investigate the role of the SIRT1/miR-223 signaling axis in neonatal sepsis.
Methods: 100 neonates with sepsis and 100 healthy infants were included in this study. The RT-qPCR was used to detect RNA and inflammatory factor levels in serum. Peripheral blood neutrophils were isolated by gradient centrifugation. LPS-stimulated neutrophils were detected for MPO activity and inflammatory factor expression. Neutrophils were transfected with miR-223 oligonucleotide and SIRT1-related plasmid to detect changes in neutrophil-related parameters.
Results: Neonates with sepsis had a significantly stronger inflammatory response than healthy infants, and the expression of miR-223 and SIRT1 in the serum was remarkably reduced. ROC curves showed that miR-223 had a diagnostic value for neonatal sepsis. The expression of miR-223 and SIRT1 was notably reduced in the model cells, and overexpression of miR-223 attenuated the inflammatory response in the LPS-induced neutrophil. Overexpression of SIRT1 could alleviate the enhanced inflammatory response due to inhibition of miR-223.
Conclusion: Overexpression of SIRT1 upregulated miR-223 expression, which attenuated the LPS-induced neutrophil activity and inflammatory response. The SIRT1/miR-223 signaling axis provides a potential therapeutic target for the clinical management of neonatal sepsis.
{"title":"Upregulation of miR-223 by SIRT1 attenuates the inflammatory response in neonatal sepsis.","authors":"Anjian Yan, Chang Lu, Xuening Wang","doi":"10.1186/s12865-025-00793-6","DOIUrl":"10.1186/s12865-025-00793-6","url":null,"abstract":"<p><strong>Background: </strong>The diversity of clinical symptoms of neonatal sepsis leads to difficulties in diagnosis, and the treatment is limited. This study aims to investigate the role of the SIRT1/miR-223 signaling axis in neonatal sepsis.</p><p><strong>Methods: </strong>100 neonates with sepsis and 100 healthy infants were included in this study. The RT-qPCR was used to detect RNA and inflammatory factor levels in serum. Peripheral blood neutrophils were isolated by gradient centrifugation. LPS-stimulated neutrophils were detected for MPO activity and inflammatory factor expression. Neutrophils were transfected with miR-223 oligonucleotide and SIRT1-related plasmid to detect changes in neutrophil-related parameters.</p><p><strong>Results: </strong>Neonates with sepsis had a significantly stronger inflammatory response than healthy infants, and the expression of miR-223 and SIRT1 in the serum was remarkably reduced. ROC curves showed that miR-223 had a diagnostic value for neonatal sepsis. The expression of miR-223 and SIRT1 was notably reduced in the model cells, and overexpression of miR-223 attenuated the inflammatory response in the LPS-induced neutrophil. Overexpression of SIRT1 could alleviate the enhanced inflammatory response due to inhibition of miR-223.</p><p><strong>Conclusion: </strong>Overexpression of SIRT1 upregulated miR-223 expression, which attenuated the LPS-induced neutrophil activity and inflammatory response. The SIRT1/miR-223 signaling axis provides a potential therapeutic target for the clinical management of neonatal sepsis.</p>","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":" ","pages":"11"},"PeriodicalIF":2.7,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Autoimmune hepatitis (AIH) is a chronic liver disease in which the immune system of the body unintentionally targets liver cells, resulting in inflammation, liver damage, and cirrhosis if treatment is not received. Although the precise origin of AIH remains unknown, experts believe that environmental and genetic factors play significant roles in its pathogenesis. This study describes the clinical, biochemical, and long-term outcomes of patients with autoimmune hepatitis (AIH) at the Science and Technology Hospital in Sana'a, Yemen.
Methodology: This was a retrospective, single-center study.
Participants: All patients with AIH diagnosed at the Science and Technology Hospital between 2019 and 2024 were included.
Results: Most patients were male (18 of 25, 72%). All patients displayed common signs and symptoms of AIH, including hepatomegaly, vomiting, jaundice, and abdominal distention. In addition to positive antinuclear antibodies (ANA) and anti-smooth muscle antibodies (ASMA), the majority of individuals showed increased AST levels. The most prevalent hematological abnormalities were thrombocytopenia (64%) and anemia (56%). Regarding the outcome after hospital admission, 60% of cases improved, 12% were discharged against medical advice, 8% died, and 20% had unknown outcomes.
Conclusion: Autoimmune hepatitis affects patients of Yemeni descent. The most common symptom is jaundice. Only Type I AIH was observed in this cohort, and the mortality rate reached 8%.
{"title":"Retrospective, single-center analysis of autoimmune hepatitis in Yemeni adults: clinical features, treatment, and outcomes.","authors":"Alariqi Reem, Al-Shami Abdulsalam, Afrah Al-Asbahy, Khalid Aldhorae, Wadee Abdullah Al-Shehari","doi":"10.1186/s12865-025-00796-3","DOIUrl":"10.1186/s12865-025-00796-3","url":null,"abstract":"<p><strong>Background: </strong>Autoimmune hepatitis (AIH) is a chronic liver disease in which the immune system of the body unintentionally targets liver cells, resulting in inflammation, liver damage, and cirrhosis if treatment is not received. Although the precise origin of AIH remains unknown, experts believe that environmental and genetic factors play significant roles in its pathogenesis. This study describes the clinical, biochemical, and long-term outcomes of patients with autoimmune hepatitis (AIH) at the Science and Technology Hospital in Sana'a, Yemen.</p><p><strong>Methodology: </strong>This was a retrospective, single-center study.</p><p><strong>Participants: </strong>All patients with AIH diagnosed at the Science and Technology Hospital between 2019 and 2024 were included.</p><p><strong>Results: </strong>Most patients were male (18 of 25, 72%). All patients displayed common signs and symptoms of AIH, including hepatomegaly, vomiting, jaundice, and abdominal distention. In addition to positive antinuclear antibodies (ANA) and anti-smooth muscle antibodies (ASMA), the majority of individuals showed increased AST levels. The most prevalent hematological abnormalities were thrombocytopenia (64%) and anemia (56%). Regarding the outcome after hospital admission, 60% of cases improved, 12% were discharged against medical advice, 8% died, and 20% had unknown outcomes.</p><p><strong>Conclusion: </strong>Autoimmune hepatitis affects patients of Yemeni descent. The most common symptom is jaundice. Only Type I AIH was observed in this cohort, and the mortality rate reached 8%.</p>","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":" ","pages":"9"},"PeriodicalIF":2.7,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12870425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145916842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}